Improved Survival Outcomes in Metastatic Colorectal Cancer Patients

Strategic Insights -

Researchers from National Cancer Center Hospital East in Japan have conducted a comprehensive study to evaluate the chronological changes in clinical outcomes associated with oxaliplatin-based doublet chemotherapy and molecular targeted agents in metastatic colorectal cancer patients. The study utilized data from the Aide et Recherche en Cancerologie Digestive (ARCAD) database, covering a period of 13 years, from 2004 to 2017, involving 5424 patients enrolled in 13 randomized controlled trials. The analysis revealed significant improvements in overall survival, progression-free survival, and post-progression survival over time, with median overall survival increasing from 21.4 months in 2004-2008 to 28.6 months in 2009-2013 and 29.7 months in 2014-2017.

Key Takeaways:

  • The study utilized data from the ARCAD database, covering a period of 13 years, from 2004 to 2017, involving 5424 patients enrolled in 13 randomized controlled trials.
  • Median overall survival improved over time, from 21.4 months (2004-2008) to 28.6 months (2009-2013) and 29.7 months (2014-2017).
  • Similar trends were observed for progression-free and post-progression survivals.
  • Multivariable analysis confirmed the treatment period as an independent prognostic factor for overall and progression-free survivals.
  • Subgroup analyses revealed improvements in overall survival for left-sided and RAS wild-type tumors, whereas minimal gains were found for right-sided or RAS-mutated tumors.
  • Increased use of subsequent therapies contributed to prolonged post-progression survival.
  • The findings highlight the importance of biomarker-driven treatment strategies and the evolving role of subsequent therapies in optimizing clinical outcomes.
  • Researchers used individual patient data meta-analyses and adjusted for key prognostic factors.
  • National Cancer Center Hospital East researchers Hideaki Bando and colleagues analyzed data from the Aide et Recherche en Cancerologie Digestive (ARCAD) database.

Statistics:

  • 5424 patients enrolled in 13 randomized controlled trials within the ARCAD database between 2004 and 2017.
  • Median overall survival increased from 21.4 months (2004-2008) to 28.6 months (2009-2013) and 29.7 months (2014-2017).
  • Increased use of subsequent therapies contributed to a 25.5% increase in post-progression survival.

Sources:

  • European Journal of Cancer: Chronological survival improvement over time with oxaliplatin-based chemotherapy plus targeted agents in metastatic colorectal cancer: An ARCAD database study. 2025;230:116034.
  • National Cancer Center Hospital East: Research conducted by Hideaki Bando and colleagues.
  • Elsevier Sci Ltd: Publisher of the European Journal of Cancer.